SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Versant V Luxco S.a r.l. (Last) (First) (Middle) 15 BOULEVARD F.W. RAIFFEISEN (Street) 2411 LUXEMBOURG N4 L-2411 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Aprea Therapeutics, Inc. [ APRE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/07/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2019		C		1,993,658	A	(1)	2,006,328	D(2)(3)(5)
Common Stock	10/07/2019		C		512,995	A	(1)	2,519,323	D(2)(3)(5)
Common Stock	10/07/2019		P		333,333	A	$15	333,333	I(4)(5)	See footnotes(4)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	(1)	10/07/2019		C			1,993,658	(1)	(1)	Common Stock	1,993,658	(1)	0	D(2)(3)(5)
Series C Convertible Preferred Stock	(1)	10/07/2019		C			512,995	(1)	(1)	Common Stock	512,995	(1)	0	D(2)(3)(5)

1. Name and Address of Reporting Person* Versant V Luxco S.a r.l. (Last) (First) (Middle) 15 BOULEVARD F.W. RAIFFEISEN (Street) 2411 LUXEMBOURG N4 L-2411 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ventures V, LLC (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ventures V GP-GP (Canada), Inc. (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ventures V (Canada), L.P. (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Venture Capital V (Canada), LP (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Affiliates Fund V, L.P. (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ophthalmic Affiliates I, L.P. (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Venture Capital V, L.P. (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

2. These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.

3. Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

4. These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

5. Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

	/s/ Versant V Luxco S.a r.l. By: Robin L. Praeger Its: Manager	10/07/2019
	/s/ Versant Ventures V, LLC By: Robin L. Praeger Its: Managing Director	10/07/2019
	/s/ Versant Ventures V GP-GP (Canada), Inc. By: Robin L. Praeger Its: Director	10/07/2019
	/s/ Versant Ventures V (Canada), L.P. By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: Robin L. Praeger Its: Director	10/07/2019
	/s/ Versant Venture Capital V (Canada) LP By: Versant Ventures V (Canada), L.P. Its: General Partner By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: Robin L. Praeger Its: Director	10/07/2019
	/s/ Versant Affiliates Fund V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director	10/07/2019
	/s/ Versant Ophthalmic Affiliates Fund I, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director	10/07/2019
	/s/ Versant Venture Capital V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director	10/07/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.